Daniel Anderson

Assistant Professor of Pharmacology at the Medical College of Georgia via Emory Healthcare and UGA College of Pharmacy

[Daniel Anderson @D_AndersonID]

@BradSpellberg @ZCiochettoMD424 Yet, unfortunately this is a direct quote from a practice guideline “streptococci usually are killed by monotherapy with antimicrobials, whereas enterococci are inhibited but not killed.”

[Brad Spellberg @BradSpellberg]

Our @wikiguidelines letter to the editor regarding the controversy between IDSA and ATS on CAP guidelines is now published. Time for societies to modernize their approach to guidelines to STOP creating care standards based on opinions. @ABsteward @DrToddLee @AnilMakam @medrants

[WikiGuidelines @Wiki_Guidelines]

Your Role: Review existing guidelines across all specialties to evaluate whether or not recommendations are based on high-quality, adequately powered, peer-reviewed, and publicly accessible prospective studies, including at least one randomized controlled trial

[WikiGuidelines @Wiki_Guidelines]

📢📢📢Join our team appraising the level of evidence used to make consensus guideline recommendations across all specialties

Deadline to sign up: 6/20/25

New to WikiGuidelines?

Use the link below to complete WikiGuidelines New Participant application. https://t.co/ibZXjf3Mwt

[Daniel Anderson @D_AndersonID]

@AU_UGAPharmRes

[Daniel Anderson @D_AndersonID]

Do empiric, adjunctive aminoglycosides improve outcomes in critically ill patients with GNR bloodstream infections? Not according to our propensity-matched observational cohort study!

[Zoheb I. Sulaiman, DO @zsulaiman13]

Check out our manuscript in @antibioticsmdpi #IDTwitter #MedEd 🦠💊🙏🏽

https://t.co/VJjkyl0PkN

@EudyJL @D_AndersonID @drdivsharma18 @MCG_AUG @mcg_id @WellstarHealth

[Daniel Anderson @D_AndersonID]

Excited to present our UTI @Wiki_Guidelines in @JAMANetworkOpen. It was an honor to work with so many brilliant clinicians and an organization whose charter I so strongly believe in.

[WikiGuidelines @Wiki_Guidelines]

We are delighted to announce the publication of UTI WikiGuideline in JAMA Network Open. Thank you to the 54 experts from 12 countries for drafting. Special thanks to @zacroBID and @amenalor for leading the effort.

https://t.co/XC2MgtjTdb

[JAMA Network Open @JAMANetworkOpen]

This consensus statement creates a clinical guideline for the diagnosis and management of UTIs that addresses the gap between the evidence and recommendation strength. https://t.co/c1nnbwewIz @bradspellberg

[WikiGuidelines @Wiki_Guidelines]

We are delighted to announce the publication of UTI WikiGuideline in JAMA Network Open. Thank you to the 54 experts from 12 countries for drafting. Special thanks to @zacroBID and @amenalor for leading the effort.

https://t.co/XC2MgtjTdb

[Daniel Anderson @D_AndersonID]

@EudyJL Thanks to our amazing study team @strmltrofomonas @Pat_TuBROmycin @ViridansPharmD @SERGE_45_ABX and others

[Daniel Anderson @D_AndersonID]

Congrats to @AU_UGAPharmRes former PGY1 Carly Loudermilk on her manuscript evaluating sequential PO therapy for E. Faecalis BSI. No difference in clinical outcomes and shorter hospital LOS in sequential PO. @UGAPharmacy @mcg_id @blandman19 @AndreaSikora https://t.co/3t5aKMD6PI

[Daniel Anderson @D_AndersonID]

IV-only patients were sicker at baseline (ICU admit but not CCI or Pitt) despite matching by source of infection. Median DOT ~2 weeks in both groups. PO patients received ~7 days of IV therapy. Was the second week of therapy necessary? @EudyJL

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕️🔥The largest real-world, multicenter study of dalbavancin use for Gram-positive BSI @NicholasRebold @IDpharmresearch and many @SIDPharm 🌟s
Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection #IDXposts #DOTS
https://t.co/FOh8iUXInq

[Daniel Anderson @D_AndersonID]

Is there an exception to #ShorterIsBetter for critically ill patients with Gram-negative BSI? Not according to our propensity-matched cohort study @EudyJL @drdivsharma18 @zsulaiman13 @ABsteward @mcg_id @AU_UGAPharmRes https://t.co/Ja0lYjxqUy

[Daniel Anderson @D_AndersonID]

@megB_thePharmD @UGAPharmacy Thank you!

[Daniel Anderson @D_AndersonID]

Thanks to the @UGAPharmacy students who make precepting such a joy! I’m humbled and honored to be recognized by this graduating class!

[UGA College of Pharmacy @UGAPharmacy]

Congratulations to the three outstanding preceptors selected to receive this year’s Preceptor of the Year Award:

- Dr. Daniel Anderson '18
- Dr. Amy Raufman Knauss '99
- Dr. Geneen Gibson

Thank you for the difference you make in the lives of our students every day!

[Daniel Anderson @D_AndersonID]

@sujitsuchindran @UGAPharmacy Thank you!

[Chris Bland @blandman19]

I see you @ABC_PharmD! Double Antibiotic Coverage Does Not Improve Outcomes in Febrile Neutropenia

https://t.co/wbIWSHGSrS

[Daniel Anderson @D_AndersonID]

Thanks to @Contagion_Live for sharing our teams work on treating ESBL UTIs!

[Contagion @Contagion_Live]

Both noncarbapenem β-lactams and #carbapenems produced good outcomes in #UTI from β-lactamase-producing #Enterobacterales #IDTwitter

https://t.co/afrznkUk9C

[ACCP INFD PRN @accpinfdprn]

🔥 NEW in OFID 🔥

👥 Retrospective cohort of admitted patients with ESBL UTI

💊 non-carbapenem beta-lactams (NCBLs) vs. carbapenems

Patients receiving NCBLs experienced:
☑️ no difference in LOS
☑️ higher rates of culture clearance
☑️ shorter DOTs

🔗 https://t.co/PBDTmJBhwq